Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04386616 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT04386616: Completed Phase 2 study, sponsored by Genentech.
NCT04386616 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 396 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04386616, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.
Primary Outcome
The time to recovery was defined as the time from baseline to a clinical status score of 1 or 2 on the 7-category ordinal scale (whichever occurs first); clinical status scores are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. No
Interventions
- DRUG MSTT1041A
- DRUG MSTT1041A-matched Placebo
- DRUG UTTR1147A
- DRUG UTTR1147A-matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2021-02-12 |
| Phase | Phase 2 |
What the finished NCT04386616 record still lists
NCT04386616 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher).
The record links to 0 conditions, and to 4 interventions - of which MSTT1041A is the first listed.
NCT04386616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04386616 about?
NCT04386616 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia". This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus ...
What is the current status of trial NCT04386616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2020-06-02. Estimated completion is 2021-02-12.
What interventions are being tested in trial NCT04386616?
The interventions under investigation include: MSTT1041A (DRUG), MSTT1041A-matched Placebo (DRUG), UTTR1147A (DRUG), UTTR1147A-matched Placebo (DRUG).
Who is sponsoring clinical trial NCT04386616?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04386616's enrollment target sits among peer trials
396 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI